Skip to main content

The independent medical news service

16-06-2022 | Oncology | News | Article

Mammogram method choice should consider breast density, cancer risk

Women with extremely dense breasts and a high breast cancer risk have a lower risk for advanced cancer when screened by digital breast tomosynthesis than digital mammography, US study findings indicate.

13-06-2022 | Oncology | News | Article

ctDNA identifies patients before late HR-positive breast cancer recurrence

Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.

09-06-2022 | Oncology | News | Article

Omitting radiotherapy may be feasible for luminal A, low-risk breast cancer

Radiotherapy may not be necessary for patients with the luminal A breast cancer intrinsic subtype and a low clinical risk for recurrence, report the LUMINA investigators.

08-06-2022 | Oncology | News | Article

Overall survival benefits shown for capivasertib in AI-resistant breast cancer

Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA/AKT1/PTEN alterations, FAKTION data show.

06-06-2022 | Oncology | News | Article

DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

Trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with HER2-low metastatic breast cancer relative to standard chemotherapy, show DESTINY-Breast04 data.

05-06-2022 | Oncology | News | Article

Ribociclib plus endocrine therapy switch benefits CDK4/6 progressors

Patients with metastatic breast cancer who progress during combination treatment with a CDK4/6 inhibitor and endocrine therapy may benefit from switching endocrine therapy and combining it with ribociclib, MAINTAIN study findings indicate.